Conversations on 
Twitter :
-
Who wants to go public now anyway? After signing another partner, Regulus in no hurry to IPO.
Input from @JohnCFierce, others - Can academics in biology secure tenure through open access journals alone?
- Is Sarepta's DMD study too small? CEO says no as analysts break-down his logic
@FierceBiotech: IMS bags planning tech for clinical trials with TTC buyout. News | Follow @FierceBiotech
@JohnCFierce: Idenix shares eviscerated as clinical hold raises tox fears. Article | Follow @JohnCFierce
@RyanMFierce: I'm planning a trip to visit my biotech neighbors to the north in Montreal. Looking forward to putting faces to names and so forth. | Follow @RyanMFierce
> FierceBiotech Editor John Carroll is keynoting the annual awards dinner for the Arizona BioIndustry Association on October 23. "We need to stay focused on the road ahead if we are to continue to keep moving forward faster," says AZBio CEO Joan Koerber-Walker. "Having John D. Carroll's global view and industry insights to share with our community will help us do just that." Story
> TG Therapeutics, a low profile biotech which went public through a merger with Manhattan recently, has completed a collaboration deal with Rhizen Pharmaceuticals on a PI3K delta inhibitor. The deal touts $250 million in potential milestones. Release
> Investor's Business Daily profiles Impax Laboratories ($IPXL), which has been developing a possibly "game-changing" Parkinson's drug. Story
Pharma News
@FiercePharma: Maybe K-V Pharma should have listened to Facebook as the Makena pricing furor grew: More | Follow @FiercePharma
> Guess who's coming to dinner, Howard? More
> Abbott's CEO paycheck bigger than its tax bill, study says. Article
> U.K. docs don't see sales reps, and don't use pharma's websites, either. Story
@FierceMedDev: Is Boston Sci still reeling from its $28B purchase of Guidant? More | Follow @FierceMedDev
@MarkHFierce: Mission accomplished: Sunshine Heart closes public offering of common stock and pulls in $18 million. Item | Follow @MarkHFierce
@DamianFierce: Regulus has signed on with Biogen Idec to develop microRNA diagnostics for MS. News | Follow @DamianFierce
> Dartmouth developing device-controlling wristwatch. Story
> FDA sticks Class I tag on Covidien recall. News
Vaccines News
> Antigen Discovery receives $2.5M grant for malaria vax. Item
> Heart disease vaccine steps closer. Report
> Feds cut Ebola vax funding. More
> FDA approves 6 flu vaccines. Story
Pharma Manufacturing News
> It is overfilled pain drug in latest Hospira recall. News
> Morphotek turns to manufacturing with new plant. Story
> West-Ward plant problems undermine Hikma earnings. Article
And Finally… Investigators say that a daily dose of chocolate could lower blood pressure, but they still recommend diet and exercise as the best approach. Story